Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSITION: Talazoparib Induction in Advanced Ovarian Cancer
NCT02316834Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2015
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Change in deoxyribonucleic acid (DNA) copy number and Change in ribonucleic acid (RNA) and protein expression. Started Jun 2015; status: completed.
02
Drugs
talazoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02316834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316834.